Recently, TRAIL is increasingly studied in the context of nonmalignant diseases, specifically metabolic diseases such as obesity, type 2 diabetes mellitus, and cardiovascular disease.10, 11 Choi et al.12 demonstrated that circulating TRAIL levels correlate positively with the body mass index (BMI) and serum lipid levels. This evidence concerns the gene TNFSF10 and obesity due to melanocortin 4 receptor deficiency.